Search

Search Constraints

You searched for: Author/Creator Schorry, Elizabeth

Search Results

1. NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. Issue 2 (22nd June 2018)

2. NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. Issue 2 (22nd June 2018)

5. Copb2 is essential for embryogenesis and hypomorphic mutations cause human microcephaly. (19th September 2017)

6. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Issue 7 (1st March 2021)

7. NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM. (4th December 2020)

8. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. (16th August 2016)

9. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. (13th December 2016)

10. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Issue 3 (17th January 2014)